title: A PLK4 inhibitor has single-agent activity in preclinical tumor models.
abstract: CFI-400945 is a potent, selective, orally bioavailable PLK4 inhibitor with antitumor activity in vivo.
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000201:enzymology*; D005260:Female; D006801:Humans; D007191:Indazoles / Q000494:pharmacology*; D007211:Indoles / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D007191:Indazoles; D007211:Indoles; D017346:Protein Serine-Threonine Kinases